Clinical Trials Directory

Trials / Suspended

SuspendedNCT02915497

Early Prevention of PTSD in Patients Within One Week of Acute Physical Trauma

A Pilot Randomized Controlled Trial in Patients Within One Week of Acute Physical Trauma to Test the Feasibility and Effectiveness of AEPET Plus RBT Versus RBT Alone for the Prevention of PTSD and Depression

Status
Suspended
Phase
N/A
Study type
Interventional
Enrollment
20 (estimated)
Sponsor
Sunnybrook Health Sciences Centre · Academic / Other
Sex
All
Age
17 Years – 75 Years
Healthy volunteers
Not accepted

Summary

The objective of this study is to assess the feasibility and effectiveness of AEPET plus Resilience Based Therapy (RBT) versus RBT alone for the prevention of PTSD and depression in trauma patients. The intervention group who have AEPET plus RBT will have reduced level of post traumatic stress symptoms and depression post sessions as well as reduced symptoms of PTSD and depression at 4- 6 weeks as compared to the control group who have -"Resilience Based" less specific supportive therapy.

Detailed description

Background: The Sunnybrook Health Sciences Centre contains one of the largest trauma centers in Canada, treating approximately 1,100 patients annually. Many of these cases typically include unexpected events that can cause severe or life-threatening injuries and at the time patients often experience horror and helplessness and even threat of death. Many of these traumatic injuries are not only physically damaging but psychologically as well. Lower psychological well-being has been reported in trauma survivors, specifically symptoms related to Depression and Post Traumatic Stress Disorder (PTSD). Methods: Patients in trauma units admitted within the previous week will be approached by a trauma team member to see if they are willing to be approached by a Research Assistant (RA). If they agree, an RA will seek permission to screen for eligibility and complete recruitment and the informed consent process. Patients will be recruited if they have a premorbid risk factor for PTSD or if their current trauma resulted in clear memories of it being life threatening and horrifying to them or resulted in dissociation. Participants will be excluded if they were intoxicated at the time of the trauma, they seem cognitively impaired or if they suffered a severe head injury. After stratified 1:1 randomization to either AEPET plus RBT (n=10-15) or RBT alone (n=10-15) , consenting participants will complete baseline measures and 3 therapy sessions, starting within 1 week post-trauma. Participants will be scheduled for their first 30-60 minute therapy session at consent . Participants will receive two more face-to-face / telephone sessions as close together as possible, followed by completing three questionnaires after the second session. In the protocol, participants will give consent within 1 week post-trauma. Eligible participants will be recruited if they are expected to remain in hospital for a minimum of 1 day to be able to complete 1 of the 3 sessions. If a patient is discharged before the second or third / final therapy session, they will be phoned for two or one remaining sessions, respectively. Participants will be included as 'treated' in the data analysis if they complete 2 out of the 3 therapy treatments. TAU will include routine psychosocial care, psychological management of trauma patients, including brief assessment and referral to psychiatry if the trauma team thinks it's necessary. RBT will specifically address the five essential intervention principles for the psychosocial management of trauma which include promotion of safety, self-efficacy, calming, connectedness and hope. The following questionnaires will be administered to patients in both the control and intervention group at baseline, 1. Stanford Acute Stress Reaction Questionnaire (SASRQ) 2. Posttraumatic Cognitions Inventory (PTCI) 3. Beck Depression Inventory II (BDI-II) The following questionnaires will be administered to patients in both the control and intervention group at baseline, with instructions to complete after their second therapy session: 1. Stanford Acute Stress Reaction Questionnaire (SASRQ) 2. Posttraumatic Cognitions Inventory (PTCI) 3. Beck Depression Inventory II (BDI-II) The following questionnaire will be administered by phone (1,2) and sent by mail (3, 4) to patients one month post enrollment in the study: 1. (by phone) Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) 2. (by phone) PTSD Symptom Scale interview (PSSI) 3. (by mail) Posttraumatic Cognitions Inventory (PTCI) 4. (by mail) Beck Depression Inventory II (BDI-II) Planned Data Analysis: Data will be analyzed using SAS. Descriptive statistics will be calculated for all variables. Bivariate comparisons of variables will be made using χ2, Spearman and Pearson correlation coefficients, Student t tests and ANOVA. Stepwise multivariable regression analyses will be undertaken to examine significant correlates of PTSD and between group (control and intervention) differences in all the outcomes. Statistical tests will be two tailed with alpha set at 0.05. The anticipated outcomes include lower levels of PTSD and depressive symptoms for those having AEPET + RBT vs. RBT alone by self report and by semi structured interview at 4-6 weeks. Significance: In testing the feasibility and effectiveness of AEPET as a novel treatment for the prevention of PTSD within its trauma ward, Sunnybrook Hospital would potentially pioneer a feasible and cost-effective method for employing a quicker response, targeted treatment for mitigating symptoms of PTSD and depression after trauma.

Conditions

Interventions

TypeNameDescription
BEHAVIORALAbbreviated Early Prolonged Exposure TherapySince many trauma patients are discharged within 4 weeks, AEPET with the same length (45 minutes - 1 hour) and number of sessions as PET, is given in a shorter time period (daily for 3 days as opposed to weekly over 3 weeks).

Timeline

Start date
2016-02-01
Primary completion
2023-08-01
Completion
2025-08-01
First posted
2016-09-27
Last updated
2024-12-05

Locations

1 site across 1 country: Canada

Source: ClinicalTrials.gov record NCT02915497. Inclusion in this directory is not an endorsement.